Daniel P Kelly1, Sigrid Bairdain2, David Zurakowski2,3, Brenda Dodson4, Kathy M Harney5, Russell W Jennings2, Cameron C Trenor5. 1. Division of Medicine Critical Care, Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Daniel.Kelly@childrens.harvard.edu. 2. Department of Pediatric Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 3. Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 4. Department of Pharmacy, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 5. Division of Hematology and Oncology, Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
PURPOSE: Patients with long-gap esophageal atresia (LGEA) treated with the Foker process are at increased risk of venous thromboembolism (VTE). An institutional quality improvement program to decrease VTE risk factor exposure and utilize prophylactic anticoagulation was implemented. We aim to evaluate the efficacy and safety of a VTE risk-reduction program in patients with LGEA. METHODS: Implementation and evaluation of a VTE risk-reduction program in patients with LGEA from 2012 to 2015 was performed. Symptomatic VTE with radiographic confirmation were defined as events. Post-program characteristics were evaluated and compared to a historical cohort. RESULTS: Sixty-seven patients were identified. Two developed VTE (7 %) post-program implementation; compared to 13/40 (33 %) VTE incidence in the historical cohort (p = 0.018). Baseline demographics were similar, including age, esophageal atresia type and gap length. Post-protocol patients had fewer paralysis episodes (p = 0.004), paralysis days (p = 0.003), central venous catheters (p = 0.003), thoracotomies (p < 0.001), ventilator hours (p = 0.02), and decreased hospital (p < 0.001) and ICU stay (p < 0.001). All patients in the VTE risk-reduction program were exposed to prophylactic anticoagulation. No bleeding complications and/or thrombosis-related mortality occurred. CONCLUSION: VTE risk-reduction program implementation decreased symptomatic VTE incidence with associated decreases in ICU and hospital length of stay. Prophylactic anticoagulation can be utilized safely in a complicated pediatric surgical population.
PURPOSE:Patients with long-gap esophageal atresia (LGEA) treated with the Foker process are at increased risk of venous thromboembolism (VTE). An institutional quality improvement program to decrease VTE risk factor exposure and utilize prophylactic anticoagulation was implemented. We aim to evaluate the efficacy and safety of a VTE risk-reduction program in patients with LGEA. METHODS: Implementation and evaluation of a VTE risk-reduction program in patients with LGEA from 2012 to 2015 was performed. Symptomatic VTE with radiographic confirmation were defined as events. Post-program characteristics were evaluated and compared to a historical cohort. RESULTS: Sixty-seven patients were identified. Two developed VTE (7 %) post-program implementation; compared to 13/40 (33 %) VTE incidence in the historical cohort (p = 0.018). Baseline demographics were similar, including age, esophageal atresia type and gap length. Post-protocol patients had fewer paralysis episodes (p = 0.004), paralysis days (p = 0.003), central venous catheters (p = 0.003), thoracotomies (p < 0.001), ventilator hours (p = 0.02), and decreased hospital (p < 0.001) and ICU stay (p < 0.001). All patients in the VTE risk-reduction program were exposed to prophylactic anticoagulation. No bleeding complications and/or thrombosis-related mortality occurred. CONCLUSION:VTE risk-reduction program implementation decreased symptomatic VTE incidence with associated decreases in ICU and hospital length of stay. Prophylactic anticoagulation can be utilized safely in a complicated pediatric surgical population.
Entities:
Keywords:
Long gap esophageal atresia; Safety; Thromboprophylaxis; Venous thromboembolism
Authors: Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Edward Vincent S Faustino; Sonya Patel; Ravi R Thiagarajan; Deborah J Cook; Veronika Northrup; Adrienne G Randolph Journal: Crit Care Med Date: 2011-07 Impact factor: 7.598
Authors: Joan Sanchez de Toledo; Sriya Gunawardena; Ricardo Munoz; Richard Orr; Donald Berry; Sara Sonderman; Sara Krallman; Dana Shiderly; Li Wang; Peter Wearden; Victor O Morell; Constantinos Chrysostomou Journal: Cardiol Young Date: 2010-03-04 Impact factor: 1.093
Authors: Sigrid Bairdain; Daniel P Kelly; Corinne Tan; Brenda Dodson; David Zurakowski; David Zurakowksi; Russell W Jennings; Cameron C Trenor Journal: J Pediatr Surg Date: 2014-02 Impact factor: 2.545